A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-Bâ„¢), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-Bâ„¢), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-Bâ„¢) in subjects with SLE disease.
This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term safety and efficacy of belimumab (LymphoStat-Bâ„¢) in subjects with SLE disease.
Inclusion Criteria:
Exclusion Criteria: